S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 181 to 240 of 278

Issue Date	Title / Author(s) / Citation	File
2018-02	Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection Kim, Hyungjin; Chae, Kum Ju; Yoon, Soon Ho; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Goo, Jin Mo; Park, Chang Min European Radiology, Vol.28 No.2, pp.861-868	DOI
2018-03	Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer Ramalingam, Suresh S.; Yang, James C. -H.; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Mann, Helen; Rukazenkov, Yuri; Ghiorghiu, Serban; Stetson, Daniel; Markovets, Aleksandra; Barrett, J. Carl; Thress, Kenneth S.; Janne, Pasi A. Journal of Clinical Oncology, Vol.36 No.9, pp.841-849	DOI
2018-03	Efficacy of pemetrexed-based chemotherapy in comparison to non-pemetrexed-based chemotherapy in advanced, ALK plus non-small cell lung cancer Jo, Jaemin; Kim, Se Hyun; Kim, Yu Jung; Lee, Juhyun; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Chung, Jin-Haeng; Jeon, Yoon Kyung; Lee, Jong Seok Yonsei Medical Journal, Vol.59 No.2, pp.202-210	view file DOI
2018-03	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody Suh, Koung Jin; Kim, Se Hyun; Kim, Yu Jung; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok Cancer Immunology, Immunotherapy, Vol.67 No.3, pp.459-470	DOI
2018-04	Phase 2 study of the HSP-90 inhibitor AUY922 in previously treated and molecularly defined patients with advanced non-small cell lung cancer Felip, Enriqueta; Barlesi, Fabrice; Besse, Benjamin; Chu, Quincy; Gandhi, Leena; Kim, Sang-We; Carcereny, Enric; Sequist, Lecia V.; Brunsvig, Paal; Chouaid, Christos; Smit, Egbert F.; Groen, Harry J. M.; Kim, Dong-Wan; Park, Keunchil; Avsar, Emin; Szpakowski, Sebastian; Akimov, Mikhail; Garon, Edward B. Journal of Thoracic Oncology, Vol.13 No.4, pp.576-584	DOI
2018-04	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Garassino, Marina Chiara; Cho, Byoung-Chul; Kim, Joo-Hang; Mazieres, Julien; Vansteenkiste, Johan; Lena, Herve; Jaime, Jesus Corral; Gray, Jhanelle E.; Powderly, John; Chouaid, Christos; Bidoli, Paolo; Wheatley-Price, Paul; Park, Keunchil; Soo, Ross A.; Huang, Yifan; Wadsworth, Catherine; Dennis, Phillip A.; Rizvi, Naiyer A.; ATLANTIC Investigators; Kim, Dong Wan The Lancet Oncology, Vol.19 No.4, pp.521-536	DOI
2018-05	Phase II study of crizotinib in east asian patients with ROS1-positive advanced non–small-cell lung cancer Wu, Yi-Long; Yang, James Chih-Hsin; Kim, Dong-Wan; Lu, Shun; Zhou, Jianying; Seto, Takashi; Yang, Jin-Ji; Yamamoto, Noboru; Ahn, Myung-Ju; Takahashi, Toshiaki; Yamanaka, Takeharu; Kemner, Allison; Roychowdhury, Debasish; Paolini, Jolanda; Usari, Tiziana; Wilner, Keith D.; Goto, Koichi Journal of Clinical Oncology, Vol.36 No.14, pp.1405-1411	DOI
2018-06	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Thoracic Cancer, Vol.9 No.6, pp.736-744	view file DOI
2018-07	Crizotinib versus chemotherapy in asian patients with alk-positive advanced non-small cell lung cancer Nishio, Makoto; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Solomon, Benjamin J.; Shaw, Alice T.; Hashigaki, Satoshi; Ohki, Emiko; Usari, Tiziana; Paolini, Jolanda; Polli, Anna; Wilner, Keith D.; Mok, Tony Cancer Research and Treatment, Vol.50 No.3, pp.691-700	view file DOI
2018-07	The effect of hospice consultation on aggressive treatment of lung cancer Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Cancer Research and Treatment, Vol.50 No.3, pp.720-728	view file DOI
2018-08	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy Lee, Jong Seok; Lee, Ki Hyeong; Cho, Eun Kyung; Kim, Dong-Wan; Kim, Sang-We; Kim, Joo-Hang; Cho, Byoung Chul; Kang, Jin Hyoung; Han, Ji-Youn; Min, Young Joo; Park, Keunchil Lung Cancer, Vol.122, pp.234-242	DOI
2018-08	Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Se Hyun; Kim, Yu Jung; Kim, Tae Min; Kim, Dong-Wan; Lee, Jong Seok; Heo, Dae Seog Esmo Open, Vol.3 No.5, p. e000332	DOI
2018-08	Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer Solomon, Benjamin J.; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Mekhail, Tarek; Felip, Enriqueta; Cappuzzo, Federico; Paolini, Jolanda; Usari, Tiziana; Tang, Yiyun; Wilner, Keith D.; Blackhall, Fiona; Mok, Tony S. Journal of Clinical Oncology, Vol.36 No.22, pp.2251-2258	DOI
2018-09	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer Cho, Byoung Chul; Dy, Grace K.; Govindan, Ramaswamy; Kim, Dong-Wan; Pennell, Nathan A.; Zalcman, Gerard; Besse, Benjamin; Kim, Joo-Hang; Koca, Goekben; Rajagopalan, Prabhu; Langer, Simon; Ocker, Matthias; Nogai, Hendrik; Barlesi, Fabrice Lung Cancer, Vol.123, pp.14-21	DOI
2018-09	Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials Camidge, D. Ross; Kim, Dong-Wan; Tiseo, Marcello; Langer, Corey J.; Ahn, Myung-Ju; Shaw, Alice T.; Huber, Rudolf M.; Hochmair, Maximilian J.; Lee, Dae Ho; Bazhenova, Lyudmila A.; Gold, Kathryn A.; Ou, Sai-Hong Ignatius; West, Howard L.; Reichmann, William; Haney, Jeff; Clackson, Tim; Kerstein, David; Gettinger, Scott N. Journal of Clinical Oncology, Vol.36 No.26, pp.2693-2701	DOI
2018-10	Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibit ROS1/TRK/ALK solvent-front mutations Drilon, Alexander; Ou, Sai-Hong Ignatius; Cho, Byoung Chul; Kim, Dong-Wan; Lees, Jeeyun; Lin, Jessica J.; Zhu, Viola W.; Ahns, Myung-Ju; Camidge, D. Ross; Nguyen, Judy; Zhai, Dayong; Deng, Wei; Huang, Zhongdong; Rogers, Evan; Liu, Juliet; Whitten, Jeff; Lim, John K.; Stopatschinskaja, Shanna; Hyman, David M.; Doebele, Robert C.; Cui, J. Jean; Shaw, Alice T. Cancer Discovery, Vol.8 No.10, pp.1227-1236	DOI
2018-11	Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer Wu, Yi-Long; Zhang, Li; Kim, Dong-Wan; Liu, Xiaoqing; Lee, Dae Ho; Yang, James Chih-Hsin; Ahn, Myung-Ju; Vansteenkiste, Johan F.; Su, Wu-Chou; Felip, Enriqueta; Chia, Vincent; Glaser, Sabine; Pultar, Philippe; Zhao, Sylvia; Peng, Bin; Akimov, Mikhail; Tan, Daniel S. W. Journal of Clinical Oncology, Vol.36 No.31, pp.3101-3109	DOI
2018-11	Virtual reality-assisted localization and three-dimensional printing-enhanced multidisciplinary decision to treat radiologically occult superficial endobronchial lung cancer Yoon, Soon Ho; Goo, Jin Mo; Lee, Chang-Hoon; Cho, Jae Young; Kim, Dong-Wan; Kim, Hak Jae; Paeng, Jin Cheol; Kim, Young Tae Thoracic Cancer, Vol.9 No.11, pp.1525-1527	view file DOI
2018-11	Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James Chih-Hsin -H.; Han, Ji-Youn; Lee, Jong-Seok; Hochmair, Maximilian J.; Li, Jacky Yu-Chung; Chang, Gee-Chen; Lee, Ki Hyeong; Gridelli, Cesare; Delmonte, Angelo; Garcia Campelo, Rosario; Kim, Dong-Wan; Bearz, Alessandra; Griesinger, Ffrank; Morabito, Alessandro; Felip, Enriqueta; Califano, Raffaele; Ghosh, Sharmistha; Spira, Alexander; Gettinger, Scott N.; Tiseo, Marcello; Gupta, Neeraj; Haney, Jeff; Kerstein, David; Popat, Sanjay New England Journal of Medicine, Vol.379 No.21, pp.2027-2039	DOI
2018-11	Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study Gadgeel, S.; Peters, S.; Mok, T.; Shaw, A. T.; Kim, D. W.; Ou, S. I.; Perol, M.; Wrona, A.; Novello, S.; Rosell, R.; Zeaiter, A.; Liu, T.; Nuesch, E.; Balas, B.; Camidge, D. R. Annals of Oncology, Vol.29 No.11, pp.2214-2222	DOI
2018-12	니볼루맙 치료 도중 발생한 폐포자충 폐렴 1예 김학로; 김범석; 박영식; 김미소; 김태민; 김동완; 허대석 대한내과학회지, Vol.93 No.6, pp.571-574	DOI
2019	Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma Kang, Seong-Ho; Keam, Bhumsuk; Ahn, Yong-Oon; Park, Ha-Ram; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog OncoImmunology, Vol.8 No.1, p. e1515057	DOI
2019-01	A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma Kim, Miso; Kim, Tae Min; Keam, Bhumsuk; Kim, Yu Jung; Paeng, Jin Chul; Moon, Kyung Chul; Kim, Dong-Wan; Heo, Dae Seog Oncologist, Vol.24 No.1, pp.20-29	DOI
2019-01	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors Kim, Ryul; Keam, Bhumsuk; Kim, Sehui; Kim, Miso; Kim, Se Hyun; Kim, Jin Wook; Kim, Yu Jung; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong-Wan; Chung, Doo Hyun; Lee, Jong Seok; Heo, Dae Seog BMC Cancer, Vol.19 No.1, p. 19	view file DOI
2019-01	The risk of herpes zoster in patients with non-small cell lung cancer according to chemotherapy regimens: Tyrosine kinase inhibitors versus cytotoxic chemotherapy Choi, Ji Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Jo, Seong Jin Cancer Research and Treatment, Vol.51 No.1, pp.169-177	view file DOI
2019-01	Significance of 18F-FDG PET parameters according to histologic subtype in the treatment outcome of stage III non–small-cell lung cancer undergoing definitive concurrent chemoradiotherapy Kim, Eunji; Wu, Hong-Gyun; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Paeng, Jin Chul; Kim, Hak Jae; Chang, Ji Hyun Clinical Lung Cancer, Vol.20 No.1, pp.E9-E23	DOI
2019-02	The role of systemic treatment in the EGFR-mutant lung cancer patients with leptomeningeal metastasis 최미홍	view file
2019-02	Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial Herbst, R. S.; Baas, P.; Perez-Gracia, J. L.; Felip, E.; Kim, D. -W.; Han, J. -Y.; Molina, J. R.; Kim, J. -H.; Arvis, C. Dubos; Ahn, M. -J.; Majem, M.; Fidler, M. J.; Surmont, V.; de Castro, G., Jr.; Garrido, M.; Shentu, Y.; Emancipator, K.; Samkari, A.; Jensen, E. H.; Lubiniecki, G. M.; Garon, E. B. Annals of Oncology, Vol.30 No.2, pp.281-289	DOI
2019-02	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS Wu, Y. -L.; Planchard, D.; Lu, S.; Sun, H.; Yamamoto, N.; Kim, D. -W.; Tan, D. S. W.; Yang, J. C. -H.; Azrif, M.; Mitsudomi, T.; Park, K.; Soo, R. A.; Chang, J. W. C.; Alip, A.; Peters, S.; Douillard, J. -Y. Annals of Oncology, Vol.30 No.2, pp.171-210	DOI
2019-02	Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis Jeong, Hoibin; Kim, Sehui; Hong, Beom-Ju; Lee, Chan-Ju; Kim, Young-Eun; Bok, Seoyeon; Oh, Jung-Min; Gwak, Seung-Hee; Yoo, Min Young; Lee, Min Sun; Chung, Seock-Jin; Defrene, Joan; Tessier, Philippe; Pelletier, Martin; Jeon, Hyeongrin; Roh, Tae-Young; Kim, Bumju; Kim, Ki Hean; Ju, Ji Hyeon; Kim, Sungjee; Lee, Yoon-Jin; Kim, Dong-Wan; Kim, Il Han; Kim, Hak Jae; Park, Jong-Wan; Lee, Yun-Sang; Lee, Jae Sung; Cheon, Gi Jeong; Weissman, Irving L.; Chung, Doo Hyun; Jeon, Yoon Kyung; Ahn, G-One Cancer Research, Vol.79 No.4, pp.795-806	DOI
2019-05	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC Barlesi, Fabrice; Garon, Edward B.; Kim, Dong-Wan; Felip, Enriqueta; Han, Ji-Youn; Kim, Joo-Hang; Ahn, Myung-Ju; Fidler, Mary Jo; Gubens, Matthew A.; de Castro, Gilberto, Jr.; Surmont, Veerle; Li, Qiao; Deitz, Anne C.; Lubiniecki, Gregory M.; Herbst, Roy S. Journal of Thoracic Oncology, Vol.14 No.5, pp.793-801	DOI
2019-05	Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report Yang, James Chih-Hsin; Shepherd, Frances A.; Kim, Dong-Wan; Lee, Gyeong-Won; Lee, Jong Seok; Chang, Gee-Chen; Lee, Sung Sook; Wei, Yu-Feng; Lee, Yun Gyoo; Laus, Gianluca; Collins, Barbara; Pisetzky, Francesca; Horn, Leora Journal of Thoracic Oncology, Vol.14 No.5, pp.933-939	DOI
2019-06	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression Schuler, Martin; Tan, Eng-Huat; O'Byrne, Kenneth; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kolbeck, Karl; Massey, Dan; Maerten, Angela; Paz-Ares, Luis; Park, Keunchil Journal of Cancer Research and Clinical Oncology, Vol.145 No.6, pp.1569-1579	DOI
2019-06	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors Park, Ha-Ram; Ahn, Yong-Oon; Kim, Tae Min; Kim, Soyeon; Kim, Seulki; Lee, Yu Soo; Kim, Miso; Keam, Bhumsuk; Kim, Dong-Wan; Heo, Dae Seog Cytotherapy, Vol.21 No.6, pp.603-611	DOI
2019-07	Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib Kim, Seulki; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Alm, Yong-Oon; Keam, Bhumsuk; Heo, Dae Seog Cancer Research and Treatment, Vol.51 No.3, pp.951-962	view file DOI
2019-07	Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 Shaw, Alice Tsang; Riely, Gregory J.; Bang, Yung-Jue; Kim, Dong-Wan; Camidge, David Ross; Solomon, Benjamin J.; Varella-Garcia, Marileila; Iafrate, Anthony John; Shapiro, Geoffrey I.; Usari, Tiziana; Wang, S. C.; Wilner, Keith. D.; Clark, Jeffrey W.; Ou, Sai Hong Ignatius Annals of Oncology, Vol.30 No.7, pp.1121-1126	DOI
2019-07	Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018 Remon, Jordi; Ahn, Myung-Ju; Girard, Nicolas; Johnson, Melissa; Kim, Dong-Wan; Lopes, Gilberto; Pillai, Rathi N.; Solomon, Benjamin; Villacampa, Guillermo; Zhou, Qing Journal of Thoracic Oncology, Vol.14 No.7, pp.1134-1155	DOI
2019-07	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP Cho, Kyoung Min; Keam, Bhumsuk; Ha, Hyerim; Kim, Miso; Jung, Jae-Woo; Song, Woo-Jung; Kim, Tae Min; Jeon, Yoon Kyung; Kang, Hye-Ryun; Kim, Dong-Wan; Kim, Chul Woo; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.34 No.4, pp.885-893	view file DOI
2019-07	Alterations in PD-L1 expression associated with acquisition of resistance to ALK inhibitors in ALK-rearranged lung cancer Kim, Su-Jung; Kim, Soyeon; Kim, Dong-Wan; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Lee, Yusoo; Koh, Jaemoon; Jeon, Yoon Kyung; Heo, Dae Seog Cancer Research and Treatment, Vol.51 No.3, pp.1231-1240	view file DOI
2019-07	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer Choi, Mihong; Keam, Bhumsuk; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Clinical Lung Cancer, Vol.20 No.4, pp.E442-E451	DOI
2019-08	Wear Life Estimation Model of Tripod Type Constant Velocity Joint Considering Adhesive Wear 김동완	view file link
2019-08	Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study Jung, Minsun; Kim, Soyeon; Lee, June-Koo; Yoon, Sun Och; Park, Heae Surng; Hong, Soon Won; Park, Weon-Seo; Kim, Ji Eun; Kim, Joon; Keam, Bhumsuk; Kim, Hyun Jik; Kang, Hyoung Jin; Kim, Dong-Wan; Jung, Kyeong Cheon; Kim, Young Tae; Heo, Dae Seog; Kim, Tae Min; Jeon, Yoon Kyung Oncologist, Vol.24 No.8, pp.E740-E748	DOI
2019-09	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial Kim, Dong-Wan; Lee, Dae Ho; Han, Ji-Youn; Lee, Jongseok; Cho, Byoung Chul; Kang, Jin Hyoung; Lee, Ki Hyeong; Cho, Eun Kyung; Kim, Jin-Soo; Min, Young Joo; Cho, Jae Yong; An, Ho Jung; Kim, Hoon-Gu; Lee, Kyung Hee; Kim, Bong-Seog; Jang, In-Jin; Yoon, Seonghae; Han, OakPil; Noh, Young Su; Hong, Ka Young; Park, Keunchil Lung Cancer, Vol.135, pp.66-72	DOI
2019-09	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis Kim, Ryul; Keam, Bhumsuk; Hahn, Seokyung; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Clinical Lung Cancer, Vol.20 No.5, pp.331-338.e4	DOI
2019-09	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer Ock, Chan-Young; Yoo, Shin-Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong Wan; Chung, Doo Hyun; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.34 No.5, pp.1116-1124	view file DOI
2019-09	Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog Journal of Thoracic Oncology, Vol.14 No.9, pp.1556-1566	DOI
2019-10	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer Kim, Yu-Jung; Keam, Bhumsuk; Ock, Chan-Young; Song, Sanghoon; Kim, Miso; Kim, Se Hyun; Kim, Ki Hwan; Kim, Jin-Soo; Kim, Tae Min; Kim, Dong-Wan; Lee, Jong Seok; Heo, Dae Seog Lung Cancer, Vol.136, pp.122-128	DOI
2019-10	The impact of social media on citation rates in coloproctology Jeong, J. W.; Kim, M. J.; Oh, H. -K; Jeong, S.; Kim, M. H.; Cho, J. R.; Kim, D. -W; Kang, S. -B Colorectal Disease, Vol.21 No.10, pp.1175-1182	DOI
2019-10	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC Antonia, Scott J.; Balmanoukian, Ani; Brahmer, Julie; Ou, Sai-Hong I.; Hellmann, Matthew D.; Kim, Sang-We; Ahn, Myung-Ju; Kim, Dong-Wan; Gutierrez, Martin; Liu, Stephen V.; Schoffski, Patrick; Jaeger, Dirk; Jamal, Rahima; Jerusalem, Guy; Lutzky, Jose; Nemunaitis, John; Calabro, Luana; Weiss, Jared; Gadgeel, Shirish; Bhosle, Jaishree; Ascierto, Paolo A.; Rebelatto, Marlon C.; Narwal, Rajesh; Liang, Meina; Xiao, Feng; Antal, Joyce; Abdullah, Shaad; Angra, Natasha; Gupta, Ashok K.; Khleif, Samir N.; Segal, Neil H. Journal of Thoracic Oncology, Vol.14 No.10, pp.1794-1806	DOI
2019-11	Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment? Yoo, Shin Hye; Ock, Chan-Young; Keam, Bhumsuk; Park, Sung Joon; Kim, Tae Min; Kim, Jin Ho; Jeon, Yoon Kyung; Chung, Eun-Jae; Kwon, Seong Keun; Hah, J. Hun; Kwon, Tack-Kyun; Jung, Kyeong Chun; Kim, Dong-Wan; Wu, Hong-Gyun; Sung, Myung-Whun; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.34 No.6, pp.1313-1323	view file DOI
2019-11	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer Heo, Ja Yoon; Park, Changhee; Keam, Bhumsuk; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Kim, Se Hyun; Kim, Yu Jung; Lee, Jong Seok; Heo, Dae Seog Thoracic Cancer, Vol.10 No.11, pp.2117-2123	view file DOI
2019-11	Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the phase ii NP28673 and NP28761 studies Gadgeel, Shirish; Shaw, Alice T.; Barlesi, Fabrice; Crino, Lucio; Yang, James C. H.; Dingemans, Anne-Marie; Kim, Dong-Wan; de Marinis, Filippo; Schulz, Mathias; Liu, Shiyao; Gupta, Ravindra; Smoljanovic, Vlatka; Ou, Sai-Hong Ignatius Lung Cancer: Targets and Therapy, Vol.10, pp.125-130	view file DOI
2019-12	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study Ahn, Myung-Ju; Han, Ji-Youn; Lee, Ki Hyeong; Kim, Sang-We; Kim, Dong-Wan; Lee, Yun-Gyoo; Cho, Eun Kyung; Kim, Joo-Hang; Lee, Gyeong-Won; Lee, Jong-Seok; Min, Young Joo; Kim, Jin-Soo; Lee, Sung Sook; Kim, Hye Ryun; Hong, Min Hee; Ahn, Jin Seok; Sun, Jong-Mu; Kim, Heung Tae; Lee, Dae Ho; Kim, Sohee; Cho, Byoung Chul The Lancet Oncology, Vol.20 No.12, pp.1681-1690	DOI
2020	Methylation analysis of thirty-three cancer types reveals an inverse correlation between methylation burden and tumor immunogenicity 박창희	view file link
2020	Preclinical modeling of Osimertinib for Epidermal Growth Factor Receptor Exon 20 Insertion Mutant Non-Small Cell Lung Cancer 이유수	view file link
2020	Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines Park, Ji-Eun; Kim, Seong-Eun; Keam, Bhumsuk; Park, Ha-Ram; Kim, Soyeon; Kim, Miso; Kim, Tae Min; Doh, Junsang; Kim, Dong-Wan; Heo, Dae Seog Journal for ImmunoTherapy of Cancer, Vol.8 No.2, p. e000873	view file DOI
2020	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma Park, Changhee; Na, Kwon Joong; Choi, Hongyoon; Ock, Chan-Young; Ha, Seunggyun; Kim, Miso; Park, Samina; Keam, Bhumsuk; Kim, Tae Min; Paeng, Jin Chul; Park, In Kyu; Kang, Chang Hyun; Kim, Dong-Wan; Cheon, Gi-Jeong; Kang, Keon Wook; Kim, Young Tae; Heo, Dae Seog Theranostics, Vol.10 No.23, pp.10838-10848	view file DOI
2020-01	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies Ahn, Myung-Ju; Han, Ji-Youn; Kim, Dong-Wan; Cho, Byoung Chul; Kang, Jin-Hyoung; Kim, Sang-We; Yang, James Chih-Hsin; Mitsudomi, Tetsuya; Lee, Jong Seok Cancer Research and Treatment, Vol.52 No.1, pp.284-291	view file DOI
2020-01	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer Ou, Sai-Hong Ignatius; Gadgeel, Shirish M.; Barlesi, Fabrice; Yang, James Chih-Hsin; De Petris, Luigi; Kim, Dong-Wan; Govindan, Ramaswamy; Dingemans, Anne-Marie; Crino, Lucio; Lena, Herve; Popat, Sanjay; Ahn, Jin Seok; Dansin, Eric; Mitry, Emmanuel; Mueller, Barbara; Bordogna, Walter; Balas, Bogdana; Morcos, Peter N.; Shaw, Alice T. Lung Cancer, Vol.139, pp.22-27	DOI
2020-01	Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial Lee, Gyeong-Won; Go, Se-Il; Kim, Dong-Wan; Kim, Hoon-Gu; Kim, Joo-Hang; An, Ho Jung; Jang, Joung Soon; Kim, Bong-Seog; Hahn, Seokyung; Heo, Dae Seog Thoracic Cancer, Vol.11 No.1, pp.62-71	view file DOI

1 2 3 4 5